I. CALL TO ORDER

a. The meeting was called to order at approximately 1:00 pm. Introductions were made by Committee members and staff.

b. Mr. Citron reported there are no new conflicts of interest to declare.

c. Election of Chair and Vice Chair
ACTION: Dr. Bill Origer nominated as Chair, All in favor, approved. Tracy Klein, PhD, FNP, nominated as Vice Chair, All in favor, approved.

d. Approval of agenda and minutes presented by Dr. Origer. (pages 4 - 8)

- Discussion of conflicts identified in regards to CF topic presented at previous P&T meeting, updates to the “Conflict of Interest” declaration form were made that should identify potential conflicts going forward. Had the newly identified conflicts been identified at the previous meeting, the P&T recommendations would likely not have changed.
- Information to be presented to the committee members must be submitted at least a week in advance.

ACTION: Motion, 2nd, Majority in Favor. Approved.

e. Department updates for OHA.

II. DUR ACTIVITIES

- Quarterly Utilization Reports (pages 9 - 13)
  Mr. Citron presented the quarterly utilization report.

- ProDUR Report (pages 14 - 16)
  Mr. Holsapple presented the quarterly ProDUR reports.

- RetroDUR Report (pages 17 - 19)
  Dr. Williams presented the quarterly RetroDUR reports.

- Oregon State Drug Reviews (pages 20 - 25)
  Dr. Sentena presented the following reviews:
  1. From Antidotes to Edoxaban: An Oral Anticoagulation Update
  2. Obesity and Related Sequelae: Are Medications the Answer?
  3. Does Sacubitril/Valsartan Pose a Treatment Conundrum for Management of Heart Failure?

III. DUR OLD BUSINESS

- Proton Pump Inhibitor Drug Policy (pages 26 - 27)
  Dr. Gibler presented the Prior Authorization Criteria.

  1. Approve proposed changes to PA criteria.

ACTION: Motion, 2nd, All in Favor. Approved.

IV. PREFERRED DRUG LIST NEW BUSINESS

- Antiemetic Drug Class Update (pages 28 - 49)
  Dr. Sentena presented the following class update:
1. No changes to the PDL based on clinical review.
2. Amend PA Criteria to allow 3 days of antiemetic therapy beyond length of treatment for patients receiving chemotherapy or radiation.
3. Add doxylamine / pyridoxine, rolapitant and the netupitant / palonosetron fixed-combination product to the Antiemetic PA for coverage of clinically appropriate OHP-funded conditions.
4. Evaluate comparative costs in executive session.

**ACTION:** Motion, 2nd, All in Favor. Approved.

b. Influenza Antiviral Class Update (pages 52 - 64)
   Dr. Gibler presented the following class update:
   1. Designate amantadine and rimantadine non-preferred.
   2. Move amantadine to the Parkinson’s Drug Class.
   3. Designate peramivir non-preferred due to limited evidence.
   4. Amend Influenza Antivirals PA and restrict to neuraminidase inhibitors only.
   5. Evaluate comparative costs in the executive session.

**ACTION:** Motion, 2nd, All in Favor. Approved.

c. Drug Class Literature Scans
   1. Immunosuppressants (pages 65 – 73)
      Dr. Herink presented the following drug class scan:
      a. No further research or review needed at this time.
      b. Evaluate comparative costs in executive session.

**ACTION:** Motion, 2nd, All in Favor. Approved.

2. Topical Analgesics (pages 74 – 82)
   Dr. Engen presented the following drug class scan:
   a. No further research or review needed at this time.
   b. Evaluate comparative costs in executive session.

**ACTION:** Motion, 2nd, All in Favor. Approved.

3. Inhaled Drugs for Cystic Fibrosis (pages 83 – 85)
   Dr. Gibler presented the following drug class scan:
   a. No further research or review needed at this time.
   b. Evaluate comparative costs in executive session.

**ACTION:** Motion, 2nd, All in Favor. Approved.

d. Iron Chelators Class Update (pages 86 – 96)
   Dr. Gibler presented the following class update:
   1. No further research or review needed at this time.
   2. Evaluate comparative costs in executive session.

**Public Comment:**
Anthony Abang from Novartis gave public comment.
**ACTION:** Motion, 2nd, All in Favor. Approved.

e. **Hepatitis C Direct-acting Antivirals Class Update (pages 97 – 123)**

Dr. Herink presented the following class update:

1. Continue to prioritize treatment for persons with advanced liver disease (METAVIR stage F3 or F4), as well as those at greatest risk of developing complications of liver disease, including:
   a. All patients awaiting a liver transplantation
   b. All patients post solid organ transplant
   c. HIV coinfection with METAVIR stage F2 or greater
   d. Patients with extrahepatic manifestations
2. Make DCV preferred and replace LDV/SOF with DCV with SOF and RBV in current prior authorization (PA) for patients with GT3 CHC with cirrhosis.
3. Due to extensive drug-drug interactions and safety concerns, make OMB/PTV-R + RBV and OMB/PTV-R + DAS non-preferred.
4. Allow treatment approval if prescribed by or in consultation with an infectious disease specialist with experience of hepatitis C.
5. Approve amended PA criteria and reorder questions regarding alcohol and illicit drug use.
6. Compare cost of DCV + SOF to alternative regimen of LDV / SOF + RBV for GT3 without cirrhosis in executive session.

**ACTION:** Motion, 2nd, Majority in Favor, 3 Opposed. Approved.

**Public Comment:**
Margaret Olmon, PharmD from AbbVie gave public comment.
Stuart O’Brochta from Gilead gave public comment.
Bridget Hernandez, PharmD from BMS gave public comment.
Steve Nemirow presented public comment.
Lorren Sandt from Caring Ambassadors gave public comment.
BJ Cavnor from One in Four gave public comment.
Dr. Kent Benner from OHSU gave public comment.

f. **Phosphate Binders Class Update**

   Deferred
2. **Phosphate Binders Literature Scan (pages 135 – 139)**
   Deferred

g. **ADHD Drug Class Update (pages 140 – 156)**
   Deferred

h. **Sodium-glucose Cotransporter 2 Inhibitor Class Update (pages 157 – 167)**
   Deferred

i. **Abbreviated Drug Reviews**

1. **Cholbam (cholic acid) (page 168)**
   Deferred
2. **Viberzi (eluxadoline) (page 169)**
   Deferred
3. **Addyi (fibanserin) (page 170)**
Deferred

4. Saxenda (liraglutide) (page 171)
Deferred

V. EXECUTIVE SESSION

VI. RECONVENE FOR PUBLIC RECOMMENDATIONS  *After executive session

a. Antiemetic Drug Class Update (pages 28 - 49)
   *ACTION: recommend no changes to the PMPDP
   Motion, 2nd, All in Favor. Approved.

b. Influenza Antiviral Class Update (pages 52 - 64)
   *ACTION: recommend no further changes to the PMPDP
   Motion, 2nd, All in Favor. Approved.

c. Immunosuppressants Scan (pages 65 – 73)
   *ACTION: recommend no changes to the PMPDP
   Motion, 2nd, All in Favor. Approved.

d. Topical Analgesics Scan (pages 74 - 82)
   *ACTION: recommend no changes to the PMPDP
   Motion, 2nd, All in Favor. Approved.

e. Inhaled Drugs for Cystic Fibrosis Scan (pages 83 – 85)
   *ACTION: recommend making Kitabis sole preferred tobramycin agent and make TOBI,
   TOBI Podhaler and generic tobramycin non-preferred on the PMPDP
   Motion, 2nd, All in Favor. Approved.

f. Iron Chelators Class Update (pages 86 – 96)
   *ACTION: recommend no changes to the PMPDP
   Motion, 2nd, All in Favor. Approved.

g. Hepatitis C Direct-acting Antivirals Class Update (pages 97 – 123)
   *ACTION: recommend LDV/SOF + RBV for GT3 without cirrhosis
   Motion, 2nd, All in Favor. Approved.

VII. ADJOURN